Please ensure Javascript is enabled for purposes of website accessibility

What's Behind Guardant Health's Disappointing Q4 Results

By Keith Speights - Feb 25, 2021 at 6:04AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company beat revenue expectations, but its bottom-line performance and 2021 outlook weren't what investors hoped for.

Guardant Health (GH -2.09%) started 2021 with a bang. The stock soared 39% year to date at one point earlier this month. It has since given up more than half of that gain, though, and its shares are likely to fall even more.  

The liquid biopsy pioneer announced its fourth-quarter results after the market closed on Wednesday. The healthcare stock slid nearly 7% in after-hours trading. Here are the highlights from Guardant Health's Q4 update.

Healthcare provider speaking with patient.

Image source: Getty Images.

By the numbers

Guardant Health reported revenue of $78.3 million in the fourth quarter, up 25% year over year. This result topped the average analyst estimate of $76.7 million.

The company announced a Q4 net loss of $93.7 million, or $0.94 per share, based on generally accepted accounting principles (GAAP). In the prior-year period, Guardant Health posted a GAAP net loss of $25.2 million, or $0.27 per share. The Wall Street consensus estimate was for a net loss of $0.57 per share in the fourth quarter of 2020.

Guardant also generated an adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) loss of $29.8 million in Q4. This reflected deterioration from the adjusted EBITDA loss of $17.1 million in the prior-year period.

Behind the numbers

Guardant Health's precision oncology revenue, which includes sales of its flagship Guardant360 product, totaled $64.7 million in the fourth quarter. This represented 13% year-over-year growth. The clinical testing component of this precision oncology revenue jumped 47% year over year, with 17,353 clinical tests performed during the quarter.

The company recorded $13.6 million in revenue from development services and other sources. This total was up 148% from the prior-year period. Guardant attributed the increase primarily to the timing of milestone payments for its companion diagnostic development programs.

That bottom-line miss in Q4 stemmed from significant spending increases. Guardant Health's operating expenses more than doubled year over year to $141.1 million. This included a stock-based compensation expense of $56.8 million, a more than tenfold year-over-year jump.

Looking ahead

Investors were also disappointed with Guardant Health's guidance for 2021. The company projects full-year revenue of between $360 million and $370 million. The midpoint of this range reflects year-over-year growth of 27.5%, well below the growth rate in 2020.

However, it's possible that Guardant Health is sandbagging its outlook somewhat. The company easily beat its revenue growth projection for 2020. It also has a new product on the market now with Guardant Reveal, a liquid biopsy for residual disease and recurrence monitoring in patients with early stage colorectal cancer.

The important thing for investors to remember is to not focus too much on a single quarter for Guardant Health. It's the kind of stock to hold for 10 years or more. The long-term prospects for Guardant Health's liquid biopsy products remain very good.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Guardant Health, Inc. Stock Quote
Guardant Health, Inc.
$36.49 (-2.09%) $0.78

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.